Evaluation of lipoprotein-associated Phospholipase A2 in Healthy Chinese Han Adult Serum

Lipids in Health and Disease

Volumn 13, Issue 1, 2014, Pages

  Feng, Li Min ^a   Feng, Guo Fang ^a   Chen, Yu ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Chinese Han adult; Lipoprotein associated phospholipase A2 (Lp PLA2); Reference interval

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BILIRUBIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY MASS; CHINESE; CHOLESTEROL BLOOD LEVEL; ERYTHROCYTE COUNT; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; LIPOPROTEIN BLOOD LEVEL; MALE; MIDDLE AGED; NORMAL HUMAN; PRACTICE GUIDELINE; SERUM; SEX DIFFERENCE; THROMBOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL; VERY ELDERLY; YOUNG ADULT;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHINA; FEMALE; HUMANS; MALE; MIDDLE AGED; REFERENCE VALUES; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 84892170365     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-13-6     Document Type: Article

References (30)

1. The growing phospholipase A2 superfamily of signal transduction enzymes. Dennis EA, Trends Biochem Sci 1997 22 1 1 2 10.1016/S0968-0004(96)20031-3 9020581 (Pubitemid 27056087)
2. Platelet-activating factor acetylhydrolase. Arai H, Prostaglandins Other Lipid Mediat 2002 68-69 83 94 (Pubitemid 35247389)
3. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Oei HH, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MM, Witteman JC, Circulation 2005 111 5 570 575 10.1161/01.CIR.0000154553.12214.CD 15699277 (Pubitemid 40216483)
4. Lipoprotein-associated phospholipase A2 activity is associated with coronary artery disease and markers of oxidative stress: a case-control study. Kim JY, Hyun YJ, Jang Y, Lee BK, Chae JS, Kim SE, Yeo HY, Jeong TS, Jeon DW, Lee JH, Am J Clin Nutr 2008 88 3 630 637 18779277
5. Association of lipoprotein-associated phospholipase A2 with coronary artery disease in African-Americans and Caucasians. Anuurad E, Ozturk Z, Enkhmaa B, Pearson TA, Berglund L, J Clin Endocrinol Metab 2010 95 5 2376 2383 10.1210/jc.2009-2498 20194707
6. Evidence supporting a key role of Lp-PLA2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammation. Goncalves I, Edsfeldt A, Ko NY, Grufman H, Berg K, Bjorkbacka H, Nitulescu M, Persson A, Nilsson M, Prehn C, et al. Arterioscler Thromb Vasc Biol 2012 32 6 1505 1512 10.1161/ATVBAHA.112.249854 22499993
7. Diagnostic value of the serum platelet-activating factor acetylhydrolase activity in inflammatory bowel disease. Oshimoto H, Okamura S, Iida T, Ishikawa T, Hosaka K, Mori M, Tohoku J Exp Med 2005 207 1 65 71 10.1620/tjem.207.65 16082157 (Pubitemid 41195360)
8. Phospholipases A2 and platelet-activating-factor acetylhydrolase in patients with acute respiratory distress syndrome. Nakos G, Kitsiouli E, Hatzidaki E, Koulouras V, Touqui L, Lekka ME, Crit Care Med 2005 33 4 772 779 10.1097/01.CCM.0000158519.80090.74 15818104
9. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. Vadas P, Gold M, Perelman B, Liss GM, Lack G, Blyth T, Simons FE, Simons KJ, Cass D, Yeung J, N Engl J Med 2008 358 1 28 35 10.1056/NEJMoa070030 18172172
10. Influence of race and gender on lipoprotein-associated phospholipase A2 levels: observations from the dallas heart study. Brilakis ES, Khera A, McGuire DK, See R, Banerjee S, Murphy SA, de Lemos JA, Atherosclerosis 2008 199 1 110 115 10.1016/j.atherosclerosis.2007.10.010 18061193 (Pubitemid 351842698)
11. Horowitz GL, Altaie S, Boyd JC, Ceriotti F, Garg U, Horn P, Pesce A, Sine HE, Zakowski J, Clinical and Laboratory Standards Institute (CLSI) C28-A3, Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory. [Approved Guideline], Volume 28 Clinical Laboratory and Standards Institute 3 2008 1 61
12. Guidelines on prevention and treatment of blood lipid abnormality. Fang Q, ZW, Ning TH, Shao G, Chen ZJ, Lu ZL, Li JZ, Lin CX, Zhou BF, Zhu JR, Hu YK, Tao P, Tao SQ, Gong LS, Gu FS, You K, Dai YH, Chinese Journal of Cardiology 1997 25 169 175
13. Spectrophotometric assay for serum platelet-activating factor acetylhydrolase activity. Kosaka T, Yamaguchi M, Soda Y, Kishimoto T, Tago A, Toyosato M, Mizuno K, Clin Chim Acta 2000 296 1-2 151 161 10807978 (Pubitemid 30243147)
14. Effect of outliers and nonhealthy individuals on reference interval estimation. Horn PS, Feng L, Li Y, Pesce AJ, Clin Chem 2001 47 12 2137 2145 11719478 (Pubitemid 33108878)
15. Lipoprotein-associated phospholipase A§ssub§2§esub§: review and recommendation of a clinical cut point for adults. Lanman RB, Wolfert RL, Fleming JK, Jaffe AS, Roberts WL, Warnick GR, McConnell JP, Prev Cardiol 2006 9 3 138 143 10.1111/j.1520-037X.2006.05547.x 16849876
16. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study. Winkler K, Winkelmann BR, Scharnagl H, Hoffmann MM, Grawitz AB, Nauck M, Bohm BO, Marz W, Circulation 2005 111 8 980 987 10.1161/01.CIR.0000156457.35971.C8 15710755 (Pubitemid 40354515)
17. Serum platelet-activating factor acetylhydrolase (PAF-AH) activity in more than 3000 healthy Japanese. Kosaka T, Yamaguchi M, Miyanaga K, Mizuno K, Clin Chim Acta 2001 312 1-2 179 183 11580924 (Pubitemid 32913595)
18. Estrogen replacement therapy decreases platelet-activating factor-acetylhydrolase activity in post-menopausal women. Yoshimura T, Ohshige A, Maeda T, Ito M, Okamura H, Maturitas 1999 31 3 249 253 10.1016/S0378-5122(99) 00004-3 10340285 (Pubitemid 29132827)
19. Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A (Lp-PLA): a review. Silva IT, Mello AP, Damasceno NR, Lipids Health Dis 2011 10 170 10.1186/1476-511X-10-170 21955667
20. Influence of obesity and cardiometabolic makers on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in adolescents: the healthy young cross-sectional study. Da Silva IT, Timm Ade S, Damasceno NR, Lipids Health Dis 2013 12 19 10.1186/1476-511X-12-19 23413990
21. Liver cells secrete the plasma form of platelet-activating factor acetylhydrolase. Tarbet EB, Stafforini DM, Elstad MR, Zimmerman GA, McIntyre TM, Prescott SM, J Biol Chem 1991 266 25 16667 16673 1653245 (Pubitemid 21907851)
22. Secretory PAF-acetylhydrolase of the rat hepatobiliary system: characterization and partial purification. Svetlov SI, Howard KM, Debuysere MS, Olson MS, Am J Physiol 1998 274 5 Pt 1 891 G900 9612271
23. Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. Stafforini DM, Tjoelker LW, McCormick SP, Vaitkus D, McIntyre TM, Gray PW, Young SG, Prescott SM, J Biol Chem 1999 274 11 7018 7024 10.1074/jbc.274.11.7018 10066756 (Pubitemid 29140510)
24. Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. Asano K, Okamoto S, Fukunaga K, Shiomi T, Mori T, Iwata M, Ikeda Y, Yamaguchi K, Biochem Biophys Res Commun 1999 261 2 511 514 10.1006/bbrc.1999. 1066 10425216 (Pubitemid 29392507)
25. Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses. Shi Y, Zhang P, Zhang L, Osman H, Mohler ER 3rd, Macphee C, Zalewski A, Postle A, Wilensky RL, Atherosclerosis 2007 191 1 54 62 10.1016/j.atherosclerosis.2006.05.001 16765356 (Pubitemid 46227429)
26. Platelet-activating factor acetylhydrolase in red cell membranes. Does decreased activity impair erythrocyte deformability in ischemic stroke patients? Yoshida H, Satoh K, Takamatsu S, Stroke 1993 24 1 14 18 10.1161/01.STR.24.1.14 8418541 (Pubitemid 23014375)
27. Comparision of inflammatory biomarkers for detection of coronary stenosis in patients with stable coronary artery disease. Uydu HA, Bostan M, Yilmaz A, Demir A, Atak M, Satiroglu Ö Temiz A, Cicek Y, Erdogan T, Cetin M, Canga A, Eur Rev Med Pharmacol Sci 2013 17 1 112 118
28. Increased lysophosphatidylcholine and non-esterified fatty acid content in LDL induces chemokine release in endothelial cells. Relationship with electronegative LDL. Benitez S, Camacho M, Arcelus R, Vila L, Bancells C, Ordonez-Llanos J, Sanchez-Quesada JL, Atherosclerosis 2004 177 2 299 305 15530903 (Pubitemid 39505261)
29. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, et al. N Engl J Med 2000 343 16 1148 1155 10.1056/NEJM200010193431603 11036120
30. Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death. May HT, Horne BD, Anderson JL, Wolfert RL, Muhlestein JB, Renlund DG, Clarke JL, Kolek MJ, Bair TL, Pearson RR, et al. Am Heart J 2006 152 5 997 1003 10.1016/j.ahj.2006.01.011 17070179 (Pubitemid 44632932)